Skip to Content
Søg Menu
December 2023

ASH | American Society of Hematology Meeting & Exposition

ASH 22

Christine Ryan

Updated results on AVO therapeutic triplet regimen in untreated patients with CLL

/ Christine Ryan
ASH22CLL Play the Video

Meet the experts: AML

Meet the experts • Akut myeloid leukæmi • Nr. 1

Get access

Late-breaking from ASH22 – Let’s keep the standard consolidation therapy with HDC-ASCT for PCNSL patients

/ BestPractice Nordic
ASH22Lymfom

Late-breaking from ASH22 – Zanubrutinib has now proven superiority to ibrutinib

/ BestPractice Nordic
ASH22LeukæmiCLL

ASH22 – Building Solutions to Challenges in Health Equity

/ BestPractice Nordic
ASH22

ASH 2022 in New Orleans – The Premier Event in Hematology 

/ BestPractice Nordic
ASH22

MEDtalks ASH 2022

CLL

Ibrutinib + venetoclax: Ny behandlingsmulighed ved CLL behandling i første linje

/ Hæmatologi / Carsten Utoft Niemann

Overlevelsesgevinst for skrøbelige CLL-patienter i behandling med Imbruvica og Venclyxto

/ Hæmatologi / Carsten Utoft Niemann

MURANO Study Supports the Use of Fixed-Duration VenR in R/R CLL

/ Hæmatologi / Arnon Kater

What is New from EHA23 Regarding Treatment Strategies in First-Line CLL?

/ Hæmatologi / Barbara Eichhorst

New Research from EHA23 Points to Similar Effectiveness of Acalabrutinib and Zanubrutinib in R/R CLL Treatment

/ Hæmatologi / Alan Z. Skarbnik
Se oversigt

AML

FLT3 Inhibitor Gilteritinib Shows Potential in Post-Transplant Maintenance for AML

/ Hæmatologi / Mark Levis

CLL – The impact of using ibrutinib as front-line treatment

/ Hæmatologi / Ryan Jacobs

Treatment Options for FLT3 mutant acute myeloid leukemia

/ Hæmatologi / Eunice Wang

Axicabtagene ciloleucel As Second-Line Therapy for Large B-Cell Lymphoma in Transplant-Ineligible Patients

/ Hæmatologi / Roch Houot

Superior efficacy of Iptacopan in PNH patients

/ Hæmatologi / Régis Peffault De Latour

Myelomatose

Daratumumab Combination Shows Positive Responses in Pretreated R/R Multiple Myeloma

/ Hæmatologi / Evangelos Terpos

EHA23 Insights into the Changing Landscape of Myeloma Treatments

/ Hæmatologi / Fredrik Schjesvold

Exciting News for CAR T Cell Therapy to Heavily Treated Patients with Multiple Myeloma

/ Hæmatologi / Sagar Lonial

Integrating BCMA-Based Combination Regimens in Early R/R Multiple Myeloma

/ Hæmatologi / Rakesh Popat

CLL – Update fra ASH 2022

/ Hæmatologi / Carsten Utoft Niemann

Lymfom

Signe Modvig

New potential key pathway in patients with ALL

/ Signe Modvig
ASH22ALL Play the Video
Jennifer R. Brown

Significant longer PFS among patients who received zanubrutinib vs ibrutinib

/ Jennifer R. Brown
ASH22CLL Play the Video
Hent flere

Mere fra ASH 2022

Matthew Davids

Several interesting combinations of therapies with Calquence for patients with CLL

/ Matthew S. Davids
ASH22CLL Play the Video
Jad Othman

UK NCRI AML19 Trial – Liposomal daunorubicin and cytarabine had a significant survival benefit

/ Jad Othman
ASH22AML Play the Video

Venetoclax plus obinutuzumab er den mest omkostningseffektive behandling af CLL uden del17p/TP53-mutationer

/ Matilde Slot
ASH22CLL Play the Video
Hent flere

MEDtalks fra ASH 2021

AML patients with FLT3-ITD and wild-type NPM1 has a significant improvement of LFS, OS and GRFS

/ Hæmatologi / Ali Bazarbachi

AML-highlights fra ASH22 – i dansk perspektiv

/ Hæmatologi / Hans Beier Ommen

Dramatic improvement in 1-year survival for patients with acute promyelocytic leukemia

/ Hæmatologi / Anand P. Jillella

New combination shows promising efficacy in patients with triple-class refractory R/R multiple myeloma

/ Hæmatologi / Paul G. Richardson

Lower-risk myelodysplastic syndromes treated with Reblozyl, luspatercept – Real-world outcomes

/ Hæmatologi / Sudipto Mukherjee

LBA ASH22: Significantly better overall survival in patients with B-lineage ALL treated with Blincyto, blinatumomab, as Consolidation Therapy

/ Hæmatologi / Mark Robert Litzow

BCMA-targeted and CAR-T cells therapies for multiple myeloma give a very exciting future and new hope for the patients

/ Hæmatologi / Sagar Lonial

Evidence to use MRD after induction therapy of AML

/ Hæmatologi / Jacqueline Cloos

R/R Large B-cell Lymphoma: Interesting results from ASH 2022 for treatment with Yescarta (axicabtagene ciloleucel)

/ Hæmatologi / Frederick L. Locke

Clinically and statistically significant improvement for efgartigimod in adults with ITP

/ Hæmatologi / Catherine M. Broome

R/R AML: The benefit of intensive remission induction chemotherapy prior to allogeneic hematopoietic cell transplantation

/ Hæmatologi / Johannes Schetelig

Genomic aberrations as prognostic factors for time-limited Venclyxto, Venetoclax-based combinations

/ Hæmatologi / Eugen Tausch

A non-restrictive diet does not increase infections in patients with neutropenia after stem cell Transplantation

/ Hæmatologi / Federico Stella

New Drugs, New Targets – Highlights from ASH22

/ Hæmatologi / Stephanie J. Lee

Promising Preliminary Efficacy in Patients with Relapsed/Refractory Multiple Myeloma

/ Hæmatologi / Paul G. Richardson

Abstracts fra ASH 2021

The ASH Annual Meeting provides several resources on COVID-19 in hematology

/ Hæmatologi / BestPractice Nordic

Long-term remission found with combination therapy for young patients with CLL

/ Hæmatologi / BestPractice Nordic

Isatuximab + RVd bedrer MRD negativitet og prognose ved myelomatose

/ Onkologi / BestPractice Nordic

New prophylactic therapy for patients with hemophilia A and B

/ Hæmatologi / BestPractice Nordic

Polatuzumab vedotin with R-CHP for patients with diffuse large B-Cell lymphoma

/ Hæmatologi / BestPractice Nordic
Se oversigt

Gå ikke glip af det nyeste fra Hæmatologi

Skriv dig på og få nye artikler, MEDtalks og magasiner i din indbakke

Send mig seneste nyt fra hæmatologi

Indhold fra ASH 2020

Post ASH: Lovende resultater for venetoclax ved behandling af AML

/ Michael Tøstesen
AMLASH20 Play the Video

ASH2020: Outcome efter CHOP-lignende behandling ved nodal perifer T-celle lymfom

/ Ahmed Ludvigsen Al-Mashhadi
LymfomT-cellerASH20 Play the Video

ASH2020: Ny fremtidig behandlingsmulighed for myelomatose

/ Agoston Gyula Szabo
MyelomatoseASH20 Play the Video
Hent flere

Back to top